

Referral to Structural Heart Clinic


 Aortic Stenosis for Transcatheter AVR vs Surgical AVR

 Mitral Regurgitation with consideration for Mitraclip

LAA occluder device with Watchman as an alternative to anticoagulation


Aortic Stenosis

- Tricuspid valve
- Progressive narrowing due to thickening and calcification of the valve.
- Risk factors:
 - Degenerative calcification- same risk factors for coronary artery disease
 - Genetics (Bicuspid valve)
 - Age
 - 6th, 7th, and 8th decades of life (tricuspid)
 - 4th, 5th, and 6th decades of life (bicuspid)
 - Chest radiation therapy



Signs/Symptoms:

- Early:
 - DOE, activity intolerance
 - Dizziness
 - Palpitations
- Late:
 - Chest discomfort/tightness
 - Syncope
 - Heart failure
- Severe symptomatic AS
 - Mortality approx 50% at two years from the onset of symptoms
 - Anticipate death within 3-5 years



Diagnostic criteria for Aortic Stenosis:

	MILD	MODERATE	SEVERE	CRITICAL
AVA	>1.5 cm2	1.0-1.5cm2	<=1.0 cm2	
Peak Velocity	2.0-2.9 m/s	3-3.9 m/s	>4.0 m/s	>5.0 m/s
Mean Gradient	<20 mmHg	20-39 mmHg	>40 mmHg	>60 mmHg

- Mild: Echocardiogram 3-5 years
- Moderate: Echocardiogram 1-2 years
- Severe: Echocardiogram 6-12 months

ACC/AHA 2017 Indications for AVR

- Class I
 - Symptomatic severe AS
 - Asymptomatic severe AS with reduced EF <50%
- Class IIa
 - Symptomatic Low flow low gradient Aortic Stenosis
 - Critical Aortic stenosis

FDA Approval for TAVR


 TAVR has become the preferred treatment for all patient subsets with severe symptomatic aortic valve stenosis:


•	Inoperable	√
•	High Risk	✓
•	Intermediate Risk	✓
•	Low Risk	✓
•	Bio prosthetic Valve	✓
•	Bicuspid Valve	√


Case Study #1


71 y/o male

- PMH: CABG x 4 with concomitant AVR with #25 Sorin 4 Mitroflow in 2012, Hypertension, Hyperlipidemia
- Echocardiogram: EF 63%, Sorin Mitroflow #25 with aortic valve area 0.9 cm2, peak velocity 5 m/s, mean gradient 60 mmHg.
- Sx: Worsening DOE x 2-3 months working on his ranch, intermittent lightheadedness, occasional chest pain. No syncope or heart failure.
- Cardiac catheterization: Patent vein grafts, no intervention.









Follow-up

Echocardiogram: 26 mm Corevalve Evolut Probio prosthesis well seated within the 25 mm
Mitroflow valve with aortic valve area 1.4 cm2,
peak velocity 2.7 m/s, mean gradient 9 mmHg.

 Symptoms: symptoms improved, mild shortness of breath

